ATOSSA THERAPEUTICS
Atossa Therapeutics is a clinical-stage biopharmaceutical company focusing on breast cancer and other breast conditions. They offer treatment for pre-cancerous breast conditions and early-stage breast cancer.
ATOSSA THERAPEUTICS
Industry:
Biotechnology Clinical Trials Genetics Health Care Therapeutics
Founded:
2009-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.atossatherapeutics.com
Total Employee:
51+
Status:
Active
Contact:
+1 206 588 0256
Total Funding:
57.8 M USD
Technology used in webpage:
Domain Not Resolving SPF Amazon Google Google Cloud Google Apps For Business Pound Sterling GoDaddy DNS Amazon Virginia Region Japanese Yen
Similar Organizations
Blue Belt Technologies
Blue Belt Technologies is a medical device company that focuses on technology and capabilities of surgical instrumentation.
Echo Therapeutics
Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) glucose monitoring system for diabetes patients.
Encoded Therapeutics
Encoded Therapeutics is a Harnessing the regulatory genome to create next-generation molecular therapies.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Gurnet Point Capital
Gurnet Point Capital is a private equity firm that invests in de-risked life sciences companies
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Instadiagnostics
Instadiagnostics Inc., is developing a rapid, quantitative, point-of-care (POC) diagnostic platform.
Telcare
Telcare develops machine-2-machine cellular technology that wirelessly connects patients and physicians to cure chronic illnesses.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Aspire Capital Partners LLC
Aspire Capital Partners LLC investment in Post-IPO Equity - Atossa Therapeutics
Keiretsu Forum Northwest
Keiretsu Forum Northwest investment in Venture Round - Atossa Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-02 | Atossa Therapeutics appoints Heather Rees as chief financial officer |
Official Site Inspections
http://www.atossatherapeutics.com Semrush global rank: 4.35 M Semrush visits lastest month: 2.28 K
- Host name: 223.54.212.35.bc.googleusercontent.com
- IP address: 35.212.54.223
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Atossa Therapeutics"
Atossa Therapeutics, Inc. (ATOS) Company Profile & Overview
Nov 8, 2012 Company profile for Atossa Therapeutics, Inc. (ATOS) with a description, list of executives, contact details and other key facts.See details»
Release Details - investors.atossatherapeutics.com
Nov 24, 2021 For more information, please visit www.atossatherapeutics.com. ABOUT TRIBE PUBLIC LLC Tribe Public LLC is a San Francisco, CA based organization that hosts …See details»
Atossa Therapeutics - Crunchbase Company Profile & Funding
Atossa Therapeutics is a biopharmaceutical company that develops therapies for breast cancer and conditions.See details»
Atossa Therapeutics, Inc. - LinkedIn
Atossa Therapeutics, Inc. Biotechnology Seattle, WA 4,451 followers Clinical-stage biopharmaceutical company developing novel, proprietary therapeutics for breast cancer and …See details»
Atossa Therapeutics | VentureRadar
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus …See details»
Release Details - Atossa Therapeutics
May 13, 2024 Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a …See details»
Release Details - Atossa Therapeutics
Dec 31, 2021 Stock-based compensation, which is a non-cash charge, increased $693 year over year. R&D compensation was also up $227 due to salary, bonus and benefit increases …See details»
Atossa Therapeutics - EverybodyWiki Bios & Wiki
Atossa Therapeutics NASDAQ : ATOS is a Seattle-based clinical-stage biopharmaceutical company. [1] [2] Atossa’s focuses on breast cancer and COVID-19. The company went public …See details»
Atossa Therapeutics Announces Year End 2020 Financial Results …
SEATTLE, March 31, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative …See details»
Atossa Therapeutics Inc, ATOS:NAQ profile - FT.com - Financial …
Nov 15, 2024 Atossa Therapeutics Inc (ATOS:NAQ) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Release Details - Atossa Therapeutics
Mar 31, 2023 About Atossa Therapeutics Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet …See details»
Atossa Genetics Announces Corporate Name Change ... - Atossa …
Jan 6, 2020 Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. …See details»
Atossa Therapeutics Provides Enrollment Update for Ongoing …
SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of …See details»
Atossa Therapeutics to Release Final Data from Phase 2
Jun 7, 2021 Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on …See details»
Atossa Therapeutics Announces Third Quarter 2022 Financial …
SEATTLE, Nov. 07, 2022 — Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on …See details»
Atossa Therapeutics Announces Year-End 2022 Financial Results …
SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to …See details»
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial …
Nov 4, 2024 Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on …See details»
Atossa Therapeutics Advances Product Development Programs …
Jul 8, 2020 Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a …See details»
Atossa Therapeutics Announces Second Quarter 2022 Financial …
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines …See details»